Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.

No abstract is available for this paper.

• Publication year

  1983

• Venue

  Laboratory investigation; a journal of technical methods and pathology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 6408310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CLINICAL AND PHARMACOLOGIC INVESTIGATION OF THE EFFECTS OF α‐TOCOPHEROL ON ADRIAMYCIN CARDIOTOXICITY *

  1982cited by this paper
• Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex.

  1982cited by this paper
• Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).

  1981cited by this paper
• Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.

  1981cited by this paper
• Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.

  1981cited by this paper
• Effect of vitamin E against adriamycin-induced toxicity in rabbits.

  1980cited by this paper
• Failure of the antioxidant vitamin E to protect against adriamycin-induced cardiotoxicity in the rabbit.

  1980cited by this paper
• Effect of sulfhydryl-containing compounds on the antitumor effects of adriamycin.

  1980cited by this paper
• Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants.

  1980cited by this paper
• Pathologic features of adriamycin toxicosis in young pigs: nonskeletal lesions.

  1979cited by this paper
• Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters.

  1979cited by this paper
• Effect of selenium-vitamin E on adriamycin-induced cardiomyopathy in rabbits.

  1978cited by this paper
• Rescue by coenzyme Q10 from electrocardiographic abnormalities caused by the toxicity of adriamycin in the rat.

  1978cited by this paper
• Effect of alpha-tocopherol on the cardiotoxicity of adriamycin in the rat.

  1978cited by this paper
• Clinical spectrum of anthracycline antibiotic cardiotoxicity.

  1978cited by this paper
• Inhibition of adriamycin‐induced human platelet lipid peroxidation by vitamin E

  1978cited by this paper
• Anthracycline cardiomyopathy monitored by morphologic changes.

  1978cited by this paper
• Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation.

  1977cited by this paper
• Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.

  1977cited by this paper
• Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats.

  1977cited by this paper
• Doxorubicin hydrochloride-associated renal failure.

  1977cited by this paper
• Vitamin E. An inhibitor of the platelet release reaction.

  1976cited by this paper
• Letter: Prevention by coenzyme Q10 (NSC-140865) of the inhibition by adriamycin (NSC-123127) of coenzyme Q10 enzymes.

  1976cited by this paper
• Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).

  1975cited by this paper
• Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943).

  1974cited by this paper

• Understanding the Mechanisms of Chemotherapy-Related Cardiotoxicity Employing hiPSC-Derived Cardiomyocyte Models for Drug Screening and the Identification of Genetic and Epigenetic Variants

  2025cites this paper
• Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane

  2025cites this paper
• Translational aspects of doxorubicin-induced cardiotoxicity: What we have omitted for the past decades?

  2025cites this paper
• Vitamin E and levocarnitine as prophylaxis against doxorubicin-induced cardio toxicity in the adult cancer patient: A review

  2022cites this paper
• Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician

  2021cites this paper
• International Harmonization of Nomenclature and Diagnostic Criteria (INHAND): Nonproliferative and Proliferative Lesions of the Minipig

  2021cites this paper
• Can antioxidant vitamins avoid the cardiotoxicity of doxorubicin in treating breast cancer?

  2021cites this paper
• Toxic Effects of Administration of Cypermethrin, Vitamin E, Zinc and Their Mixtures on the Hormonal Levels of Thyroid, Kidney Functions and some Biochemical Parameters in Male Mice

  2020cites this paper
• Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines In Vitro

  2019cites this paper
• An update on the mechanisms related to cell death and toxicity of doxorubicin and the protective role of nutrients.

  2019cites this paper
• The cardioprotective effect of dexrazoxane (Cardioxane) is consistent with sequestration of poly(ADP-ribose) by self-assembly and not depletion of topoisomerase 2B

  2018cites this paper
• Long-term intake of white tea prevents oxidative damage caused by adriamycin in kidney of rats.

  2016cites this paper
• The minipig as a new model for the evaluation of doxorubicin‐induced chronic toxicity

  2016cites this paper
• Dexrazoxane Shows No Protective Effect in the Acute Phase of Reperfusion during Myocardial Infarction in Pigs

  2016cites this paper
• Dexrazoxane for the treatment of chemotherapy-related side effects

  2014cites this paper
• Dexrazoxane for the treatment of chemotherapy-related side effects

  2014cites this paper
• Dexrazoxane for the treatment of chemotherapy-related side effects

  2014cites this paper
• Dexrazoxane for the treatment of chemotherapy-related side effects

  2014cites this paper
• Dexrazoxane for the treatment of chemotherapy-related side effects

  2014cites this paper
• The role of antioxidants in the era of cardio-oncology

  2013cites this paper
• Doxorubicin-Induced Oxidative Injury of Cardiomyocytes - Do We Have Right Strategies for Prevention?

  2012cites this paper
• The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat.

  2010cites this paper
• Morphine is protective against doxorubicin-induced cardiotoxicity in rat.

  2008cites this paper
• Adriamycin-induced myocardial toxicity: new solutions for an old problem?

  2007cites this paper
• Activity of d,l-alpha-tocopherol (vitamin E) against cardiotoxicity induced by doxorubicin and doxorubicin with cyclophosphamide in mice.

  2005cites this paper
• Influence of DL α-lipoic acid and vitamin-E against doxorubicin-induced biochemical and histological changes in the cardiac tissue of rats

  2005cites this paper
• The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer

  2004cites this paper
• Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits

  2004cites this paper
• Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog

  2004cites this paper
• The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients

  2004cites this paper
• Amifostine protection against doxorubicin cardiotoxicity in rats

  2004cites this paper
• Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity

  2004cites this paper
• Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159)

  2004cites this paper
• The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat

  2004cites this paper
• Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats

  2004cites this paper
• Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.

  2004cites this paper
• Antioxidant nutrients and adriamycin toxicity.

  2002cites this paper
• New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity.

  2001cites this paper
• Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats

  2000cites this paper
• 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week.

  2000cites this paper
• Anthracycline-induced cardiotoxicity.

  2000cites this paper
• CARDIOPROTECTION

  1999cites this paper
• Preclinical models of cardiac protection and testing for effects of dexrazoxane on doxorubicin antitumor effects.

  1998cites this paper
• Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity.

  1998cites this paper
• Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.

  1998cites this paper
• Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.

  1998cites this paper
• Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.

  1997cites this paper
• Animal models of heart failure recent developments and perspectives.

  1997cites this paper
• Free radicals and antioxidants in chemotherapy-induced toxicity.

  1997cites this paper
• Recent Developmentsand Perspectives

  1997cites this paper
• Long-Lasting Effect of Dexrazoxane Against Anthracycline Cardiotoxicity in Rats

  1996cites this paper
• Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice A new model to test potential protectors

  1996cites this paper
• PROTECTIVE EFFECT OF SOBUZOXANE (MST-16) AGAINST ADRIAMYCIN-INDUCED CARDIOTOXICITY IN THE RABBIT

  1996cites this paper
• Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.

  1996cites this paper
• Monohydroxyethylrutoside as protector against chronic doxorubicin‐induced cardiotoxicity

  1995cites this paper
• Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.

  1994cites this paper
• Dexrazoxane in the Prevention of Doxorubicin-Induced Cardiotoxicity

  1994cites this paper
• Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.

  1994cites this paper
• The syndrome of 5‐fluorouracil cardiotoxicity. An elusive cardiopathy

  1993cites this paper
• Enzymatic ring-opening reactions of the chiral cardioprotective agent (+) (S)-ICRF-187 and its (-) (R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase.

  1993cites this paper
• The role of biotransformation in anthracycline-induced cardiotoxicity in mice.

  1993cites this paper
• Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.

  1993cites this paper
• The removal of metal ions from transferrin, ferritin and ceruloplasmin by the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] and its hydrolysis product ADR-925

  1993cites this paper
• Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.

  1993cites this paper
• An Unexpected Hydrolysis pH-Rate Profile, at pH Values Less than 7, of the Labile Imide, ICRF-187: (+)-1,2-Bis-(3,5 -dioxopiperazin-1-yl)propane

  1992cites this paper
• Is ICRF-187 [(+)-1,2-Bis(3,5-dioxopiperazinyl-1-yl)propane] Unusually Reactive for an Imide?

  1992cites this paper
• Effect of ICRF-187 on the pulmonary damage induced by hyperoxia in the rat.

  1992cites this paper
• Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.

  1992cites this paper
• ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.

  1991cites this paper
• Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity.

  1991cites this paper
• Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.

  1991cites this paper
• Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reduction.

  1991cites this paper
• The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane.

  1991cites this paper
• Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.

  1990cites this paper
• The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).

  1990cites this paper
• The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane)

  1990cites this paper
• Myocardial damage induced by doxorubicins: hydroperoxide-initiated chemiluminescence and morphology.

  1990cites this paper
• Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy.

  1990cites this paper
• Dioxopiperazines: chemistry and biology.

  1990cites this paper
• Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).

  1990cites this paper
• The Adriamycin (doxorubicin)-induced inactivation of cytochrome c oxidase depends on the presence of iron or copper.

  1989cites this paper
• Pharmacokinetics and central haemodynamic effects of doxorubicin and 4'epi-doxorubicin in the pig.

  1989cites this paper
• The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin

  1989cites this paper
• Free radical formation by antitumor quinones.

  1989cites this paper
• ICRF 187.

  1989cites this paper
• Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.

  1988cites this paper
• The Role of Prenylamine in the Prevention of Adriamycin-Induced Cardiotoxicity. A Review of Experimental and Clinical Findings

  1988cites this paper
• Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.

  1988cites this paper
• Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.

  1988cites this paper
• Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.

  1988cites this paper
• [Role of vitamins E and C in the development of the malignant process].

  1986cites this paper
• Myocardial diseases of animals.

  1986cites this paper
• Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E.

  1986cites this paper
• Mitigation of an anthracycline-induced cardiomyopathy by pretreatment with razoxane: a quantitative morphological assessment

  1986cites this paper
• Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice.

  1986cites this paper
• Effect of selenium deficiency on the chronic toxicity of adriamycin in rats.

  1986cites this paper
• Free radical‐induced pathology

  1985cites this paper
• Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.

  1985cites this paper
• Comparison of Lipid Peroxidation and Myocardial Damage Induced by Adriamycin and 4′-Epiadriamycin in Mice

  1985cites this paper
• Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats.

  1985cites this paper